Clockwise from left: Caitlyn Miller, Carolyn Bertozzi, Ronald Levy and Jennifer Cochran
June 25, 2024 07:00 AM EDTUpdated 04:33 PM
Financing
Startups

New can­cer biotech emerges from Stan­ford re­search, with help of No­bel lau­re­ate Car­olyn Bertozzi

Kyle LaHucik

Senior Reporter

A new sol­id tu­mor biotech based on re­search out of Stan­ford Uni­ver­si­ty is tar­get­ing the red-hot fields of can­cer im­munother­a­py and an­ti­body-drug con­ju­gates.

TwoStep Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

Au­toim­mune brain dis­ease start­up Ar­ialys gets new leader; In­tel­lia, Arv­inas ap­point CFOs

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

To tack­le a dead­ly brain dis­ease, sci­en­tists de­vise small but charm­ing epi­ge­net­ic edit­ing tool

A service from the Financial Times